DLL3 and neuroendocrine carcinoma: While these recent findings have strengthened the position of DLL3 as a protein of interest for these hard-to-treat cancers, limited data preclude conclusions about DLL3’s potential therapeutic role in other types of pulmonary NEN, extrapulmonary NEN and also non-neuroendocrine carcinomas.